查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595128

非处方药市场：按产品和分销管道划分 - 2025-2030 年全球预测

Over The Counter Drugs Market by Product (Analgesics, Cough, Cold, & Flu Products, Dermatology Products), Distribution Channel (Hospital Pharmacies, Online Stores, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年非处方药市值为4,641.4亿美元，预计到2024年将达到5,048.6亿美元，复合年增长率为8.86%，预计到2030年将达到8,412亿美元。

非处方药（OTC）市场是指无需处方笺即可购买的药品，可以让消费者独立治疗感冒、头痛、过敏等小病。对成药的需求是由自我治疗需求不断增长以及线上医疗保健资讯的不断增加所推动的，这使得消费者能够做出明智的健康决定。成药的主要用途包括止痛药、胃肠治疗、皮肤科和营养食品。最终用途范围主要包括透过药局、超级市场和网路零售通路直接面向消费者的销售。市场成长受到人口老化、零售药局连锁扩张以及监管转向将处方药重新分类为非处方药以降低医疗保健成本等因素的显着影响。数位健康平台将进一步改善消费者获得成药的机会，并为市场参与者提供肥沃的土壤。为了满足永续性的永续发展需求，产品创新存在潜在机会，包括开发副作用较少的先进配方和环保包装。儘管市场预计将稳定成长，但它面临着重大挑战，包括各个司法管辖区的严格监管以及误用和过度使用非处方药的风险。也存在一些限制，包括激烈的竞争和价格压力，特别是来自学名药的压力。公司可以专注于创新领域，例如个人化 OTC 解决方案，利用人工智慧和机器学习来分析客户资料并提供客製化产品。此外，整合远端医疗服务可以提高消费者的信任和参与。该市场竞争激烈，但充满活力，受到消费者对便利、安全和健康意识不断变化的偏好的推动。强烈建议供应商所有者利用资料分析和策略伙伴关係关係来应对这些复杂性并确保主动遵守监管规范，同时利用新兴趋势来维持市场领先地位。

主要市场统计
基准年[2023] 4641.4亿美元
预测年份 [2024] 5048.6亿美元
预测年份 [2030] 8412亿美元
复合年增长率（%） 8.86%

市场动态：揭示快速发展的非处方药市场的关键市场洞察

非处方药市场正在因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 治疗轻微健康问题的经济有效的方法
    • 减轻医生负担
    • 有利的法规结构
  • 市场限制因素
    • 由于市场饱和而存在替代药物
  • 市场机会
    • 增加透过零售店和超级市场的管道
    • 技术进步与产品创新
  • 市场挑战
    • 保持低价的压力

波特五力：驾驭非处方药市场的策略工具

波特五力是了解非处方药市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对非处方药市场的影响

外部宏观环境因素对非处方药市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解非处方药市场的竞争状况

对非处方药市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵非处方药市场供应商绩效评估

FPNV定位矩阵是评估非处方药市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 绘製非处方药市场的成功之路

对于希望加强在全球市场的影响力的公司来说，非处方药市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 治疗轻微健康问题的经济有效的方法
      • 减轻医生负担
      • 首选法规结构
    • 抑制因素
      • 由于市场饱和而存在替代药物
    • 机会
      • 改善透过零售店和超级市场的访问
      • 技术进步与产品创新
    • 任务
      • 保持低价的压力
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 非处方药市场：副产品

  • 止痛药
  • 预防咳嗽、感冒和流感的产品
  • 皮肤科产品
  • 胃肠医学
  • 眼科产品
  • 助眠剂
  • 维生素、矿物质和补充品
  • 减重/减肥产品

第七章 非处方药市场：依分销管道

  • 医院药房
  • 网路商店
  • 零售药房

第8章：美洲非处方药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太非处方药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的非处方药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alembic Pharmaceuticals Ltd.
  • Alkem Laboratories Limited
  • Cipla, Inc.
  • Dr. Reddy's Laboratories
  • Glaxosmithkline PLC
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs Ltd.
  • Johnson & Johnson Pvt. Ltd.
  • Lupin Limited
  • Mankind Pharma
  • Mylan Pharmaceuticals Pvt. Ltd. by Viatris
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-436297358D26

The Over The Counter Drugs Market was valued at USD 464.14 billion in 2023, expected to reach USD 504.86 billion in 2024, and is projected to grow at a CAGR of 8.86%, to USD 841.20 billion by 2030.

The Over-the-Counter (OTC) drugs market refers to pharmaceuticals that can be purchased without a prescription, allowing consumers to manage minor ailments such as colds, headaches, and allergies independently. The necessity of OTC drugs stems from the rising demand for self-medication and the increasing accessibility of healthcare information online, empowering consumers to make informed health decisions. Key applications of OTC drugs include pain relief, gastrointestinal treatments, dermatology, and dietary supplements. End-use scope primarily involves direct consumer sales through drugstores, supermarkets, and online retail channels. Market growth is significantly influenced by factors such as an aging population, the expansion of retail pharmacy chains, and regulatory shifts towards reclassifying prescription drugs as OTC to decrease healthcare costs. Digital health platforms further enhance consumer access to OTC medications, representing a fertile ground for market players. Potential opportunities lie in product innovation, such as developing advanced formulations with fewer side effects and eco-friendly packaging to meet the rising demand for sustainability. Despite robust growth prospects, the market faces significant challenges such as stringent regulations across varying jurisdictions and the risk of misuse or overuse of OTC products. Other limitations include intense competition and pricing pressures, especially from generic alternatives. Companies can focus on innovative areas such as personalized OTC solutions using AI and machine learning to analyze customer data for tailored product offerings. Additionally, integrating telehealth services can enrich consumer trust and engagement. The market's nature is highly competitive yet dynamic, driven by evolving consumer preferences towards convenience, safety, and health consciousness. Vendors are urged to leverage data analytics and strategic partnerships to navigate these complexities, ensuring proactive compliance with regulatory norms while capitalizing on emerging trends to sustain market leadership.

KEY MARKET STATISTICS
Base Year [2023] USD 464.14 billion
Estimated Year [2024] USD 504.86 billion
Forecast Year [2030] USD 841.20 billion
CAGR (%) 8.86%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Over The Counter Drugs Market

The Over The Counter Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Cost effective way to treat minor health issues
    • Reduced burden of the physician
    • Favorable regulatory framework
  • Market Restraints
    • Presence of substitute drug due to saturating market
  • Market Opportunities
    • Increased accessibility through retail outlets and supermarkets
    • Technological advancement and product innovation
  • Market Challenges
    • Pressure to keep the price low

Porter's Five Forces: A Strategic Tool for Navigating the Over The Counter Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Over The Counter Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Over The Counter Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Over The Counter Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Over The Counter Drugs Market

A detailed market share analysis in the Over The Counter Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Over The Counter Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Over The Counter Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Over The Counter Drugs Market

A strategic analysis of the Over The Counter Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Over The Counter Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Ltd., Alkem Laboratories Limited, Cipla, Inc., Dr. Reddy's Laboratories, Glaxosmithkline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Ltd., Johnson & Johnson Pvt. Ltd., Lupin Limited, Mankind Pharma, Mylan Pharmaceuticals Pvt. Ltd. by Viatris, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Over The Counter Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Analgesics, Cough, Cold, & Flu Products, Dermatology Products, Gastrointestinal Products, Ophthalmic Products, Sleeping Aids, Vitamins, Mineral, & Supplements, and Weight-Loss & Dietary Products.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Stores, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Cost effective way to treat minor health issues
      • 5.1.1.2. Reduced burden of the physician
      • 5.1.1.3. Favorable regulatory framework
    • 5.1.2. Restraints
      • 5.1.2.1. Presence of substitute drug due to saturating market
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased accessibility through retail outlets and supermarkets
      • 5.1.3.2. Technological advancement and product innovation
    • 5.1.4. Challenges
      • 5.1.4.1. Pressure to keep the price low
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Over The Counter Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Analgesics
  • 6.3. Cough, Cold, & Flu Products
  • 6.4. Dermatology Products
  • 6.5. Gastrointestinal Products
  • 6.6. Ophthalmic Products
  • 6.7. Sleeping Aids
  • 6.8. Vitamins, Mineral, & Supplements
  • 6.9. Weight-Loss & Dietary Products

7. Over The Counter Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Stores
  • 7.4. Retail Pharmacies

8. Americas Over The Counter Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Over The Counter Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Over The Counter Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals Ltd.
  • 2. Alkem Laboratories Limited
  • 3. Cipla, Inc.
  • 4. Dr. Reddy's Laboratories
  • 5. Glaxosmithkline PLC
  • 6. Glenmark Pharmaceuticals Limited
  • 7. Hetero Drugs Ltd.
  • 8. Johnson & Johnson Pvt. Ltd.
  • 9. Lupin Limited
  • 10. Mankind Pharma
  • 11. Mylan Pharmaceuticals Pvt. Ltd. by Viatris
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. OVER THE COUNTER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OVER THE COUNTER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OVER THE COUNTER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OVER THE COUNTER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH, COLD, & FLU PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GASTROINTESTINAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OPHTHALMIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SLEEPING AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS, MINERAL, & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY WEIGHT-LOSS & DIETARY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 107. OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023